home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 05/14/20

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP

Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to a...
AIM - RIOT, WIX among premarket gainers

Applied DNA Sciences (NASDAQ: APDN ) +71%  after receiving FDA emergency use authorization for COVID-19 test. More news on: Applied DNA Sciences, Inc., AIM ImmunoTech Inc., Immunic, Inc., Stocks on the move, , Read more ...

AIM - AIM ImmunoTech +34% after FDA authorizes ampligen trial in COVID-19 patients

The FDA has authorized AIM ImmunoTech (NYSEMKT: AIM ) the first human trial assessing the safety and effectiveness of Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19. More news on: AIM ImmunoTech Inc., Healthcare stocks news, Stocks on th...

AIM - AIM ImmunoTech EPS misses by $0.12

AIM ImmunoTech (NYSEMKT: AIM ): Q1 GAAP EPS of -$0.22 misses by $0.12 . More news on: AIM ImmunoTech Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

AIM - AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020

Ended the First Quarter of 2020 with Cash, Cash Equivalents and Marketable Securities of $31.1 Million OCALA, FL / ACCESSWIRE / May 14, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that the U.S. Food and Drug Administration has authorized the first human trial assessin...

AIM - Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has received written comments from the U.S. Food and Drug Administration (FDA) ...

AIM - TransGlobe Energy Corporation Announces AGM Voting Results and Confirmation of Board Changes

AIM & TSX:  “TGL” & NASDAQ:  “TGA” CALGARY, Alberta, May 14, 2020 (GLOBE NEWSWIRE) -- TransGlobe Energy Corporation (“TransGlobe” or the “Company”) announces its AGM voting results. Report in Respect of Voting...
AIM - Tiziana Life Sciences Announces Data Demonstrating StemPrintER's Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused ...

AIM - Atalaya Mining PLC Announces 1st Quarter Financial Results

NICOSIA, CYPRUS / ACCESSWIRE / May 14, 2020 / Atalaya Mining Plc (AIM:ATYM)(TSX:AYM), is pleased to announce its unaudited quarterly results for the three months ended 31 March 2020 ("Q1 2020"), together with the unaudited, condensed, interim consolidated financial statements. The Q1 2020 U...

AIM - Transglobe Energy Corporation Announces First Quarter 2020 Financial and Operating Results for the Three Months Ended March 31, 2020

This Announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 (“MAR”). Upon the publication of this Announcement, this inside information is now considered to be in the public domain. AIM & TSX:  “TGL...
Previous 10 Next 10